Hoth Therapeutics, Inc.
NASDAQRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Hoth Therapeutics, Inc. (NASDAQ: HOTH) develops therapies targeting dermatological disorders, oncology support, neurological conditions, and metabolic diseases; its lead product HT-001, a topical epidermal growth factor receptor inhibitor, advances in Phase 2 CLEER-001 trials for EGFR-inhibitor-induced rash in cancer patients, demonstrating strong safety and efficacy trends; HT-KIT, with FDA Orphan Drug Designation for systemic mastocytosis, completes IND-enabling toxicology studies targeting IND filing in 2026 and features over 80% c-Kit suppression in preclinical models; HT-ALZ, an oral thin film NK1R modulator for Alzheimer's patients with swallowing difficulties, progresses through GLP toxicology, pharmacokinetics, and CNS penetration studies; and a new GDNF-based program licensed via joint venture with Silo Pharma from the U.S. Department of Veterans Affairs addresses obesity, non-alcoholic fatty liver disease, and metabolic dysfunction. The company, founded in 2017 and headquartered in New York, New York, operates primarily in the United States with global intellectual property expansion including Japan Patent No. 7677628 for HT-KIT through 2039; recent developments encompass EMA submission for HT-001 Phase 2 expansion, partnerships with Atlanta VA Center, ICON Clinical Research, Lantern Pharma's AI platform achieving 94% blood-brain barrier prediction accuracy, Aronnax for HT-KIT dosing, LTS Therapy Systems for HT-ALZ, and Weill Cornell Medicine for inflammatory bowel disease research; treasury reserve expansion to include up to $1 million in Bitcoin, Ethereum, and Solana; and CEO Robb Knie's presentation at NobleCon21.
Why Hoth Therapeutics (HOTH) Stock Is Surging After Hours Today
Hoth Therapeutics Becomes Rocket One Inc. (Nasdaq: RKTO), Targeting the Space Economy with Next-Generation Nanomagnetic AI Chip Technology and Ultra-Low-Power, Radiation-Tolerant Computing for Space and Defense Applications
Hoth Therapeutics Awarded U.S. Patent for Cancer-Fighting HT-KIT Oncology Platform
AI Chip Energy Efficiency: Hoth Therapeutics Restructures as Rocket One Inc. to Enter the AI Semiconductor Infrastructure Market with Acquisition of Exclusive Rights to Next Generation AI Semiconductor Acceleration Technology Built on Non-Volatile Nanomagnetic Semiconductor Architecture
Hoth Therapeutics Secures European Authorization in Spain for HT-001 Phase 2a Trial as Interim Data Show Strong Efficacy in Cancer Patients
Hoth Therapeutics (HOTH) Reports Positive HT-VA CRADA Data: GDNF Reprograms Liver Fat Metabolism, Shuts Down Fat-Creation Gene and Activates Fat-Burning Pathways, Outperforming Semaglutide
Hoth Therapeutics (HOTH) Reports Positive HT-VA CRADA Data: GDNF Reprograms Liver Fat Metabolism, Shuts Down Fat-Creation Gene and Activates Fat-Burning Pathways, Outperforming Semaglutide
Hoth Therapeutics Announces Closing of $2.0 Million Registered Direct Offering
Hoth Therapeutics Announces $2.0 Million Registered Direct Offering
Hungary Approves Trial Expansion as HT-001 Meets Primary Endpoint in Interim Analysis with Patients Reaching ARIGA ≤1 by Week Six
Hoth Therapeutics Announces Issuance of Chinese Patent for Cancer Cell-Targeting Technology
Hoth Therapeutics Deploys OpenClaw™ AI Platform to Accelerate Drug Discovery
Hoth Therapeutics Reports Positive HT-001 PK, Safety, and Clinical Activity Data in Cancer Patients with EGFR Therapy-Associated Skin Toxicities Showing ~77% Increase in Drug Exposure and Minimal Systemic Absorption
Hoth Therapeutics Reports Positive Female Preclinical Data Showing HT-VA Restores Cholesterol Levels and Improves Lipid Metabolism in MASLD Model
Hoth Therapeutics Deploys OpenAI API to Advance Development of Orphan HT-KIT Oncology Program
HOTH THERAPEUTICS ACCELERATES HT-001 TRIAL ENROLLMENT WITH NEW CLINICAL SITE AS PATIENT DEMAND INCREASES
Hoth Therapeutics Announces Groundbreaking Positive Results: Hoth's HT-VA GDNF Surpasses Semaglutide in Weight Loss, Glucose Control, and Liver Health in Obesity Model
EXCLUSIVE: Small Biotech Hoth Therapeutics Claims Experimental Obesity Drug Topped Famed Wegovy In Preclinical Study
Hoth Therapeutics Addresses Market Rumor, Hoth Holds No Crypto Currency Assets
Hoth Therapeutics Delivers 100% Clinical Response with ~50% Reduction in Disease Severity in Open-Label PK Cohort of EGFR-Treated Cancer Patients